Double up for Korbinian Löbmann

Korbinian Löbmann is Chief Scientific Officer at Zerion Pharma, which he also co-founded in 2019. The company was founded after several years of research at the University of Copenhagen.

“We have developed a formulation platform to improve the bioavailability of drugs by increasing their solubility,” he says.

In simple terms, the technique involves converting poorly soluble molecular drugs into an amorphous structure to make them dissolve quicker in the body. The idea is to improve bioavailability in this way.

“We are currently working with partner companies from the pharmaceutical industry testing Zerion’s Dispersome technology on their own proprietary drugs. We are also working on reformulating a previously marketed drug that we want to bring to market.”

He is looking forward to moderating New Updates in Drug Formulation & Bioavailability on 6 September and The Future of Swedish & Danish Life Science on 7 September.

He has met many people in the industry during his years as the moderator of the former conference.

“Over the years, I have encountered several companies with different new approaches to drug formulation, which proves that more than ever, there is a need for new ways to formulate drugs, as those currently available in the industry have certain limitations.”

Korbinian Löbmann feels that Sweden and Denmark have a thriving life science industry. The event in Lund highlights the sector in both countries, and he is looking forward to meeting the speakers and moderating the conference.